Tokyo Tape
Sign in
← Medinet

Annual report

2370.TEDINET S100PT7B
Period2021-10-01 → 2022-09-30
Filed2022-12-15
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 92
MetricValuePeriodScopeSource row
Revenue¥634m2021-10-01 → 2022-09-30StandaloneNet sales
Revenue¥683m2020-10-01 → 2021-09-30StandaloneNet sales
Revenue¥783m2019-10-01 → 2020-09-30dStandaloneNet sales (5-year summary)
Revenue¥1.1bn2018-10-01 → 2019-09-30dStandaloneNet sales (5-year summary)
Revenue¥998m2017-10-01 → 2018-09-30dStandaloneNet sales (5-year summary)
Revenue¥958m2017-10-01 → 2018-09-30dStandaloneNet sales (5-year summary)
Operating income−¥1.3bn2021-10-01 → 2022-09-30StandaloneOperating income
Operating income−¥1.1bn2020-10-01 → 2021-09-30StandaloneOperating income
Ordinary income−¥1.3bn2021-10-01 → 2022-09-30StandaloneOrdinary income
Ordinary income−¥871m2020-10-01 → 2021-09-30StandaloneOrdinary income
Ordinary income−¥837m2019-10-01 → 2020-09-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥995m2018-10-01 → 2019-09-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥2.7bn2017-10-01 → 2018-09-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥2.7bn2017-10-01 → 2018-09-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.2bn2021-10-01 → 2022-09-30StandaloneIncome before income taxes
Profit before tax−¥838m2020-10-01 → 2021-09-30StandaloneIncome before income taxes
Net income (owners)−¥3.0bn2017-10-01 → 2018-09-30dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income−¥1.3bn2021-10-01 → 2022-09-30StandaloneProfit loss
Net income−¥843m2020-10-01 → 2021-09-30StandaloneProfit loss
Net income−¥842m2019-10-01 → 2020-09-30dStandaloneNet income loss (5-year summary)
Net income−¥795m2018-10-01 → 2019-09-30dStandaloneNet income loss (5-year summary)
Net income−¥3.1bn2017-10-01 → 2018-09-30dStandaloneNet income loss (5-year summary)
Total assets¥6.1bnat 2022-09-30StandaloneAssets
Total assets¥5.4bnat 2021-09-30StandaloneAssets
Total assets¥5.2bnat 2020-09-30dStandaloneTotal assets (5-year summary)
Total assets¥3.1bnat 2019-09-30dStandaloneTotal assets (5-year summary)
Total assets¥3.9bnat 2018-09-30dStandaloneTotal assets (5-year summary)
Total assets¥3.9bnat 2018-09-30dStandaloneTotal assets (5-year summary)
Total liabilities¥566mat 2022-09-30StandaloneLiabilities
Total liabilities¥475mat 2021-09-30StandaloneLiabilities
Net assets / equity¥5.5bnat 2022-09-30StandaloneNet assets
Net assets / equity¥4.9bnat 2021-09-30StandaloneNet assets
Net assets / equity¥4.8bnat 2020-09-30dStandaloneNet assets
Net assets / equity¥2.6bnat 2019-09-30dStandaloneNet assets (5-year summary)
Net assets / equity¥3.3bnat 2018-09-30dStandaloneNet assets (5-year summary)
Net assets / equity¥3.3bnat 2018-09-30dStandaloneNet assets (5-year summary)
Cash and deposits¥4.5bnat 2022-09-30StandaloneCash and deposits
Cash and deposits¥4.1bnat 2021-09-30StandaloneCash and deposits
Cash & equivalents¥4.5bnat 2022-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.1bnat 2021-09-30StandaloneCash and cash equivalents
Cash & equivalents¥3.6bnat 2020-09-30dStandaloneCash and cash equivalents
Cash & equivalents¥1.4bnat 2019-09-30dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥2.2bnat 2018-09-30dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.2bn2021-10-01 → 2022-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥975m2020-10-01 → 2021-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥633m2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥938m2018-10-01 → 2019-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥2.5bn2017-10-01 → 2018-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥20m2021-10-01 → 2022-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥344m2020-10-01 → 2021-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥86m2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥50m2018-10-01 → 2019-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥154m2017-10-01 → 2018-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.6bn2021-10-01 → 2022-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2020-10-01 → 2021-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥2.8bn2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥90m2018-10-01 → 2019-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2017-10-01 → 2018-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-6.332021-10-01 → 2022-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-4.882020-10-01 → 2021-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.192019-10-01 → 2020-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.712018-10-01 → 2019-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-26.772017-10-01 → 2018-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-27.472017-10-01 → 2018-09-30dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥26.03at 2022-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥27.31at 2021-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥29.6at 2020-09-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥21.1at 2019-09-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥27.56at 2018-09-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥27.03at 2018-09-30dStandaloneNet assets per share (5-year summary)
Equity ratio90.7%at 2022-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio90.8%at 2021-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio90.7%at 2020-09-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2019-09-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.8%at 2018-09-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2018-09-30dStandaloneEquity to asset ratio (5-year summary)
ROE-24.1%2021-10-01 → 2022-09-30StandaloneRate of return on equity (5-year summary)
ROE-17.5%2020-10-01 → 2021-09-30StandaloneRate of return on equity (5-year summary)
ROE-23.0%2019-10-01 → 2020-09-30dStandaloneRate of return on equity (5-year summary)
ROE-27.7%2018-10-01 → 2019-09-30dStandaloneRate of return on equity (5-year summary)
ROE-70.0%2017-10-01 → 2018-09-30dStandaloneRate of return on equity (5-year summary)
ROE-72.2%2017-10-01 → 2018-09-30dStandaloneRate of return on equity (5-year summary)
Shares issued211,730,423at 2022-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued178,750,423at 2021-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued160,830,423at 2020-09-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued120,875,423at 2019-09-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued118,230,423at 2018-09-30dStandaloneTotal number of issued shares (5-year summary)
Employees96at 2022-09-30StandaloneNumber of employees
Employees83at 2021-09-30StandaloneNumber of employees
Employees78at 2020-09-30dStandaloneNumber of employees
Employees76at 2019-09-30dStandaloneNumber of employees
Employees92at 2018-09-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2021-10-01 → 2022-09-30¥13m
Reconciling Itemsreconcilingdepreciation2021-10-01 → 2022-09-30¥22m
Reconciling Itemsreconcilingsegment assetsat 2022-09-30¥5.3bn
Reconciling Itemsreconcilingsegment profit2021-10-01 → 2022-09-30−¥518m
Cellular And Tissue Based Product Businessreportable segmentcapex2021-10-01 → 2022-09-30¥4m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2021-10-01 → 2022-09-30¥28m
Cellular And Tissue Based Product Businessreportable segmentemployeesat 2022-09-3019 pure
Cellular And Tissue Based Product Businessreportable segmentrevenue2021-10-01 → 2022-09-30¥221,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2021-10-01 → 2022-09-30¥221,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2022-09-30¥147m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2021-10-01 → 2022-09-30−¥582m
Contracted Cell Manufacturing Businessreportable segmentcapex2021-10-01 → 2022-09-30¥60m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2021-10-01 → 2022-09-30¥56m
Contracted Cell Manufacturing Businessreportable segmentemployeesat 2022-09-3065 pure
Contracted Cell Manufacturing Businessreportable segmentrevenue2021-10-01 → 2022-09-30¥633m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2021-10-01 → 2022-09-30¥633m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2022-09-30¥643m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2021-10-01 → 2022-09-30−¥233m
—segment totalcapex2021-10-01 → 2022-09-30¥64m
—segment totaldepreciation2021-10-01 → 2022-09-30¥84m
—segment totalrevenue2021-10-01 → 2022-09-30¥634m
—segment totalrevenue external2021-10-01 → 2022-09-30¥634m
—segment totalsegment assetsat 2022-09-30¥790m
—segment totalsegment profit2021-10-01 → 2022-09-30−¥815m
Reconciling Itemsreconcilingcapex2020-10-01 → 2021-09-30¥8m
Reconciling Itemsreconcilingdepreciation2020-10-01 → 2021-09-30¥23m
Reconciling Itemsreconcilingsegment assetsat 2021-09-30¥4.6bn
Reconciling Itemsreconcilingsegment profit2020-10-01 → 2021-09-30−¥497m
Cellular And Tissue Based Product Businessreportable segmentcapex2020-10-01 → 2021-09-30¥7m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2020-10-01 → 2021-09-30¥34m
Cellular And Tissue Based Product Businessreportable segmentrevenue2020-10-01 → 2021-09-30¥206,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2020-10-01 → 2021-09-30¥206,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2021-09-30¥157m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2020-10-01 → 2021-09-30−¥451m
Contracted Cell Manufacturing Businessreportable segmentcapex2020-10-01 → 2021-09-30¥18m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2020-10-01 → 2021-09-30¥58m
Contracted Cell Manufacturing Businessreportable segmentrevenue2020-10-01 → 2021-09-30¥683m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2020-10-01 → 2021-09-30¥683m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2021-09-30¥666m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2020-10-01 → 2021-09-30−¥132m
—segment totalcapex2020-10-01 → 2021-09-30¥25m
—segment totaldepreciation2020-10-01 → 2021-09-30¥92m
—segment totalrevenue2020-10-01 → 2021-09-30¥683m
—segment totalrevenue external2020-10-01 → 2021-09-30¥683m
—segment totalsegment assetsat 2021-09-30¥824m
—segment totalsegment profit2020-10-01 → 2021-09-30−¥583m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,053
ItemContextValueUnit
Net cash provided by used in financing activities (5-year summary)CurrentYearDuration_NonConsolidatedMember1584835000JPY
Cash and cash equivalents (5-year summary)Prior4YearInstant_NonConsolidatedMember－JPY
Cash and cash equivalents (5-year summary)Prior3YearInstant_NonConsolidatedMember1403718000JPY
Cash and cash equivalents (5-year summary)Prior2YearInstant_NonConsolidatedMember3643814000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant_NonConsolidatedMember4095689000JPY
Cash and cash equivalents (5-year summary)CurrentYearInstant_NonConsolidatedMember4499095000JPY
Number of employeesPrior4YearInstant_NonConsolidatedMember92
Number of employeesPrior3YearInstant_NonConsolidatedMember76
Number of employeesPrior2YearInstant_NonConsolidatedMember78
Number of employeesPrior1YearInstant_NonConsolidatedMember83
Number of employeesCurrentYearInstant_NonConsolidatedMember96
Average number of temporary workersPrior4YearInstant_NonConsolidatedMember30
Average number of temporary workersPrior3YearInstant_NonConsolidatedMember17
Average number of temporary workersPrior2YearInstant_NonConsolidatedMember17
Average number of temporary workersPrior1YearInstant_NonConsolidatedMember19
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember18
Total shareholder returnPrior4YearInstant_NonConsolidatedMember0.672
Total shareholder returnPrior3YearInstant_NonConsolidatedMember0.477
Total shareholder returnPrior2YearInstant_NonConsolidatedMember0.695
Total shareholder returnPrior1YearInstant_NonConsolidatedMember0.547
Total shareholder returnCurrentYearInstant_NonConsolidatedMember0.766
Total return on share price indexPrior4YearInstant_NonConsolidatedMember1.108
Total return on share price indexPrior3YearInstant_NonConsolidatedMember0.993
Total return on share price indexPrior2YearInstant_NonConsolidatedMember1.042
Total return on share price indexPrior1YearInstant_NonConsolidatedMember1.329
Total return on share price indexCurrentYearInstant_NonConsolidatedMember1.234
Number of employeesCurrentYearInstant_NonConsolidatedMember96
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember18
Average age years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember38.6
Average length of service years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember8.5
Average annual salary information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember5378438JPY
Number of employeesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember65
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember10
Number of employeesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember19
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember4
Number of employeesCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember12
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember4
Number of employeesCurrentYearInstant_NonConsolidatedMember96
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember18
Research and development expenses research and development activitiesCurrentYearDuration565224000JPY
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember29291000JPY
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember535932000JPY
Capital expenditures overview of capital expenditures etcCurrentYearDuration76994000JPY
Capital expenditures overview of capital expenditures etcCurrentYearDuration_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember59590000JPY
Capital expenditures overview of capital expenditures etcCurrentYearDuration_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember4033000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember211730423
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember211730423
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant211730423
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant211730423
Number of shares constituting one unitCurrentYearInstant_OrdinaryShareMember100

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2021-09-30pass rounding
balance sheet identitynon_consolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2020-09-30pass
statement vs summary · net assetsnon_consolidated 2021-09-30pass
statement vs summary · net assetsnon_consolidated 2022-09-30pass
statement vs summary · operating cash flownon_consolidated 2020-10-01/2021-09-30pass
statement vs summary · operating cash flownon_consolidated 2021-10-01/2022-09-30pass
statement vs summary · revenuenon_consolidated 2020-10-01/2021-09-30pass
statement vs summary · revenuenon_consolidated 2021-10-01/2022-09-30pass
statement vs summary · total assetsnon_consolidated 2021-09-30pass
statement vs summary · total assetsnon_consolidated 2022-09-30pass